However, SFV treatment, especially with the IFNγ transgene, effectively counteracted this polarisation, inducing M1 markers like Nos2, Cxcl9, Cxcl10 and Cxcl11. This reprogramming could enhance anti-tumour immune responses by promoting the recruitment and activation of effector T cells within the tumour milieu. This evidence concerns the gene CXCL9 and neoplasm.